- Home
- SRBK vs LUCD Comparison
SRBK vs LUCD Comparison
Compare SRBK & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.18
Company Overview
Basic Information| Metric | SRBK | LUCD |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.7M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRBK | LUCD |
|---|---|---|
| Price | $15.92 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 38.2K | ★ 684.1K |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 374.69 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $31,130,000.00 | $4,399,000.00 |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | N/A | $147.43 |
| P/E Ratio | $29.09 | ★ N/A |
| Revenue Growth | 0.85 | ★ 5.01 |
| 52 Week Low | $11.36 | $0.80 |
| 52 Week High | $17.11 | $1.80 |
Technical Indicators
Market Signals| Indicator | SRBK | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 60.34 |
| Support Level | $15.65 | $1.12 |
| Resistance Level | $16.10 | $1.15 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 24.43 | 96.67 |
Price Performance
Historical Comparison SRBK
LUCD
About SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.